During the drug development pipeline for a novel beta-blocker designed to manage hypertension, the candidate drug progresses from preclinical testing to clinical trials. Which of the following describes the protocol and rationale for Phase I clinical trials?
The drug is administered in small, escalating doses to a small group of healthy volunteers to assess safety and determine how the drug is metabolised in the human body.
The drug is tested on a large sample of patients (typically 1,000–3,0001{,}000\text{--}3{,}0001,000–3,000) using a randomised, double-blind design to compare its efficacy against currently prescribed hypertensive medications.
The drug is administered to animal models with induced hypertension to establish the therapeutic index, safe dosage ranges, and potential organ toxicity.
The drug is prescribed to a medium-sized group of patients (typically 100–300100\text{--}300100–300) suffering from hypertension to determine the optimum therapeutic dose and monitor short-term efficacy.
97 exam-style questions on OCR GCSE Biology 6.3 Monitoring and maintaining health, covering 6.3.1 Health and disease, 6.3.2 Interactions between diseases, 6.3.3 Spread of communicable diseases, 6.3.4 Common infections and diseases, 6.3.5 Physical plant defence responses, 6.3.6 Chemical plant defence responses, 6.3.7 Detecting and identifying plant diseases, 6.3.8 White blood cells and platelets, 6.3.9 Non-specific defence systems, 6.3.10 The immune system, 6.3.11 Monoclonal antibodies, 6.3.12 Vaccines and medicines, 6.3.13 Aseptic techniques, 6.3.14 Discovery and development of new medicines, 6.3.15 Causes of non-communicable diseases, 6.3.16 Treatments for cardiovascular disease, 6.3.17 Lifestyle factors and non-communicable diseases, 6.3.18 Cancer, 6.3.19 Stem cells in medicine, 6.3.20 Gene technology in medicine, and 6.3.21 The human genome and medicine. Each one has a worked solution and a mark scheme showing where the marks go.